What is the 13F Pro Quality Score for AHCO?

13F Pro ranks AdaptHealth Corp. (AHCO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AHCO's current score at https://13fpro.ai/research/AHCO (free sign-up required for the full ranking).

Where does 13F Pro source AHCO data?

All AdaptHealth Corp. fundamentals and ownership data come directly from SEC EDGAR. AdaptHealth Corp. files with the SEC under CIK 1725255. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AHCO in?

AdaptHealth Corp. (AHCO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is AHCO research updated on 13F Pro?

AHCO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

AdaptHealth Corp.(AHCO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1725255 AHCO stock profile & AI dashboard →

13F Pro Quality Score

47.9/100

Rank #1,585 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

37.1/100

Profitability

55.7/100

Balance Sheet

37.9/100

Earnings Quality

30.0/100

Free Cash Flow

46.0/100

Institutional Flow

23.9/100

Revenue Scale

71.2/100

Dilution Risk

68.0/100

AHCO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for AdaptHealth Corp. (AHCO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AHCO at 47.9/100 on a 32-signal composite quality model, placing it at rank #1,585 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (23.9) and earnings quality (30.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), AdaptHealth Corp. reports quarterly revenue of $819.8M, net income of $-16.0M, an operating margin of 0.7%. Top institutional holders of AHCO by reported 13-F value include OEP CAPITAL ADVISORS, L.P., BlackRock,, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), based on the most recent SEC filings. AHCO trades on the Nasdaq exchange and files with the SEC under CIK 1725255. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AHCO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AdaptHealth Corp. directly from SEC EDGAR. AdaptHealth Corp.'s 13F Pro composite quality score has ranged between 8 and 61 since 2021, currently 47.9 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about AdaptHealth Corp.

Quirks, history, and lore behind AHCO — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare services company · mid-cap · listed on Nasdaq · headquartered in Pennsylvania.
2
The Numbers
Generates roughly $3 billion in annual revenue and serves over 3 million patients across the United States — not bad for a company most people have never heard of.
3
The History
Founded in 2012, it grew rapidly through an aggressive acquisition strategy, snapping up dozens of smaller home medical equipment providers to stitch together a national network.
4
The Secret
It doesn't run hospitals or clinics — it delivers medical equipment directly to patients' homes, think sleep therapy devices, oxygen, and wheelchairs billed straight to insurance.
5
The Lore
The company rode a massive wave during the COVID-19 pandemic, as demand for home-based care and respiratory equipment surged and Wall Street briefly fell in love with its growth story.
6
The Giveaway
Its name practically writes the job description: a company built to help patients adapt to managing chronic conditions at home, with a ticker that sounds like a friendly acronym for 'actually helpful care, okay.'

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$819.8M

Net Income

Q1 2026

$-16.0M

Free Cash Flow

Q1 2026

$-27.5M

Operating Margin

Q1 2026

0.7%

ROIC

Q1 2026

0.2%

D/E Ratio

Q1 2026

1.23

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+1.4% YoY

$3.24BFY 2025

FY21 $2.45BFY22 $2.97BFY23 $3.20BFY25 $3.24B

Net Income

+89.6% YoY

$-70.8MFY 2025

FY21 $156.2MFY22 $69.3MFY23 $-678.9MFY25 $-70.8M

Operating Income

+115.2% YoY

$90.9MFY 2025

FY21 $225.6MFY22 $190.4MFY23 $-598.4MFY25 $90.9M

EPS (Diluted)

+90.2% YoY

$-0.52FY 2025

FY21 $0.67FY22 $0.33FY23 $-5.31FY25 $-0.52

Total Assets

-4.3% YoY

$4.32BFY 2025

FY21 $5.25BFY22 $5.22BFY23 $4.51BFY25 $4.32B

Total Debt

-20.2% YoY

$1.76BFY 2025

FY21 $2.22BFY22 $2.22BFY23 $2.20BFY25 $1.76B

Op. Cash Flow

+25.2% YoY

$601.8MFY 2025

FY21 $275.7MFY22 $373.9MFY23 $480.7MFY25 $601.8M

Metric	FY 2025	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$3.24B +1.4%	$3.20B +7.7%	$2.97B +21.0%	$2.45B +132.4%	$1.06B +99.5%	$529.6M
Net Income	$-70.8M +89.6%	$-678.9M -1079.4%	$69.3M -55.6%	$156.2M +196.6%	$-161.6M -657.4%	$-21.3M
Operating Income	$90.9M +115.2%	$-598.4M -414.3%	$190.4M -15.6%	$225.6M +216.2%	$71.3M +142.9%	$29.4M
EPS (Diluted)	$-0.52 +90.2%	$-5.31 -1709.1%	$0.33 -50.7%	$0.67 +121.8%	$-3.08 -224.2%	$-0.95
Total Assets	$4.32B -4.3%	$4.51B -13.6%	$5.22B -0.6%	$5.25B +189.5%	$1.81B +232.1%	$546.1M
Total Debt	$1.76B -20.2%	$2.20B -1.0%	$2.22B -0.0%	$2.22B +180.4%	$792.9M +98.9%	$398.6M
Operating Cash Flow	$601.8M +25.2%	$480.7M +28.6%	$373.9M +35.6%	$275.7M +40.9%	$195.6M +223.8%	$60.4M

AI Insight: AHCO Ratio Trends

A severe Q4 2025 loss (-8.7% operating margin, -27.1% ROE) has dragged TTM profitability deeply negative, erasing the momentum built through 2024.

• Operating margin collapsed from 11.4% in Q4 2024 to -8.7% in Q4 2025, signaling a material one-off charge or structural deterioration.

• ROIC turned deeply negative at -8.9% in Q4 2025, versus a peak of 10.9% in Q4 2024 — a 19.8pp swing in one year.

• Leverage has modestly improved; D/E fell from 1.43 in Q2 2024 to 1.10 in Q3 2025, though it has since ticked back to 1.23.

• Q1 2026 operating margin recovered slightly to 0.7% from -8.7%, but remains far below the 3.0% posted in Q1 2025.

⚠ Q4 2025 loss driver must be clarified — whether one-time impairment or recurring, it determines if recovery to mid-single-digit margins is achievable.

⚠ TTM NPM of -2.4% and ROA of -1.8% confirm losses are not yet contained; sustained negative returns could pressure the balance sheet.

⚠ D/E edging back up to 1.23 in Q1 2026 after reaching 1.10 warrants monitoring, especially alongside negative earnings.

Get alerted when AHCO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for AdaptHealth Corp. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AHCO

OEP CAPITAL ADVISORS, L.P.
$194.1M16,312,698 sh
BlackRock, Inc.
$189.7M15,939,953 sh
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$136.6M11,477,730 sh
REINHART PARTNERS, LLC.
$120.0M10,081,983 sh
SkyKnight Capital, L.P.
$102.1M8,580,443 sh
FMR LLC
$95.9M8,054,691 sh
DIMENSIONAL FUND ADVISORS LP
$82.4M6,920,973 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$72.7M6,105,860 sh
VANGUARD CAPITAL MANAGEMENT LLC
$53.5M4,498,018 sh
STATE STREET CORP
$51.2M4,299,148 sh

Fund	Value	Shares
OEP CAPITAL ADVISORS, L.P.	$194.1M	16,312,698
BlackRock, Inc.	$189.7M	15,939,953
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	$136.6M	11,477,730
REINHART PARTNERS, LLC.	$120.0M	10,081,983
SkyKnight Capital, L.P.	$102.1M	8,580,443
FMR LLC	$95.9M	8,054,691
DIMENSIONAL FUND ADVISORS LP	$82.4M	6,920,973
VANGUARD PORTFOLIO MANAGEMENT LLC	$72.7M	6,105,860
VANGUARD CAPITAL MANAGEMENT LLC	$53.5M	4,498,018
STATE STREET CORP	$51.2M	4,299,148

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AHCO on your watchlist

Track score changes the day AdaptHealth Corp. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AHCO a good stock to buy?

13F Pro's AI-powered analysis of AdaptHealth Corp. (AHCO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AHCO are available on the AHCO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own AHCO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AHCO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of AdaptHealth Corp.'s investment landscape.